Baxalta options rights to six immuno-oncology projects from Symphogen; could pay up to $1.78bn
Executive Summary
Symphogen AS granted Baxalta Inc. options to exclusively license global rights to six immuno-oncology projects against undisclosed checkpoint targets. Specific targets and indications were not disclosed.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice